HHS should look beyond restricting prescription drug rebates in Medicare Part D as a way to encourage lower list prices and focus instead on changes converting all the compensation provided to pharmacy benefit managers, wholesalers and pharmacies to a fee, according to the Pharmaceutical Research and Manufacturers of America.
PhRMA offers what it describes as a “bold new policy position” in July 16 comments to HHS. The submission responds...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?